News Image

Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.

By Mill Chart

Last update: Jul 24, 2024

Our stock screener has singled out BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) as an attractive growth opportunity. NASDAQ:BMRN is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.


Affordable growth stocks image

Looking at the Growth

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:BMRN has earned a 7 for growth:

  • The Earnings Per Share has grown by an impressive 200.00% over the past year.
  • Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 13.74% in the last year.
  • Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.16% on average per year.
  • BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.08% yearly.
  • Based on estimates for the next years, BMRN will show a quite strong growth in Revenue. The Revenue will grow by 11.86% on average per year.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Valuation Assessment of NASDAQ:BMRN

An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:BMRN has received a 6 out of 10:

  • Compared to the rest of the industry, the Price/Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.95% of the companies listed in the same industry.
  • Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 93.73% of the companies are valued more expensively.
  • Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 94.43% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 95.30% of the companies listed in the same industry.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BMRN has a very decent profitability rating, which may justify a higher PE ratio.
  • BMRN's earnings are expected to grow with 63.06% in the coming years. This may justify a more expensive valuation.

Understanding NASDAQ:BMRN's Health

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:BMRN, the assigned 5 for health provides valuable insights:

  • BMRN has an Altman-Z score of 6.01. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
  • BMRN has a better Altman-Z score (6.01) than 79.79% of its industry peers.
  • The Debt to FCF ratio of BMRN (6.67) is better than 94.95% of its industry peers.
  • A Debt/Equity ratio of 0.12 indicates that BMRN is not too dependend on debt financing.
  • A Current Ratio of 2.74 indicates that BMRN has no problem at all paying its short term obligations.

Profitability Analysis for NASDAQ:BMRN

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:BMRN, the assigned 7 is noteworthy for profitability:

  • BMRN's Return On Assets of 2.99% is amongst the best of the industry. BMRN outperforms 94.77% of its industry peers.
  • With an excellent Return On Equity value of 4.05%, BMRN belongs to the best of the industry, outperforming 95.12% of the companies in the same industry.
  • BMRN has a better Return On Invested Capital (2.42%) than 94.25% of its industry peers.
  • The Profit Margin of BMRN (8.31%) is better than 95.64% of its industry peers.
  • The Operating Margin of BMRN (7.17%) is better than 94.43% of its industry peers.
  • Looking at the Gross Margin, with a value of 79.23%, BMRN belongs to the top of the industry, outperforming 86.93% of the companies in the same industry.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

Our latest full fundamental report of BMRN contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (10/4/2024, 8:08:07 PM)

After market: 69.51 0 (0%)

69.51

+1.35 (+1.98%)

Follow us for more